<?xml version='1.0' encoding='utf-8'?>
<document id="11724087"><sentence text="Possible interaction of zopiclone and nefazodone."><entity charOffset="24-33" id="DDI-PubMed.11724087.s1.e0" text="zopiclone" /><entity charOffset="38-48" id="DDI-PubMed.11724087.s1.e1" text="nefazodone" /><pair ddi="false" e1="DDI-PubMed.11724087.s1.e0" e2="DDI-PubMed.11724087.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s1.e0" e2="DDI-PubMed.11724087.s1.e1" /></sentence><sentence text="To describe a case in which concurrent treatment with nefazodone was associated with an elevation in the plasma concentration of zopiclone, possibly resulting in enhanced hypnosedative efficacy"><entity charOffset="54-64" id="DDI-PubMed.11724087.s2.e0" text="nefazodone" /><entity charOffset="129-138" id="DDI-PubMed.11724087.s2.e1" text="zopiclone" /><pair ddi="false" e1="DDI-PubMed.11724087.s2.e0" e2="DDI-PubMed.11724087.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s2.e0" e2="DDI-PubMed.11724087.s2.e1" /></sentence><sentence text="" /><sentence text="An 86-year-old white woman was treated with nefazodone for depression"><entity charOffset="44-54" id="DDI-PubMed.11724087.s4.e0" text="nefazodone" /></sentence><sentence text=" Zopiclone was also introduced for the management of insomnia, but she subsequently experienced morning drowsiness"><entity charOffset="1-10" id="DDI-PubMed.11724087.s5.e0" text="Zopiclone" /></sentence><sentence text=" The concentration of zopiclone in plasma was subsequently measured eight hours after administration on two occasions, during nefazodone therapy and after its withdrawal"><entity charOffset="22-31" id="DDI-PubMed.11724087.s6.e0" text="zopiclone" /><entity charOffset="126-136" id="DDI-PubMed.11724087.s6.e1" text="nefazodone" /><pair ddi="false" e1="DDI-PubMed.11724087.s6.e0" e2="DDI-PubMed.11724087.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s6.e0" e2="DDI-PubMed.11724087.s6.e1" /></sentence><sentence text=" After discontnuation of nefazodone, the plasma concentration of the S-enantiomer of zopiclone decreased from 107 to 16"><entity charOffset="25-35" id="DDI-PubMed.11724087.s7.e0" text="nefazodone" /><entity charOffset="85-94" id="DDI-PubMed.11724087.s7.e1" text="zopiclone" /><pair ddi="false" e1="DDI-PubMed.11724087.s7.e0" e2="DDI-PubMed.11724087.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s7.e0" e2="DDI-PubMed.11724087.s7.e1" /></sentence><sentence text="9 ng/mL, while the R-enantiomer plasma concentration decreased from 20" /><sentence text="6 to 1" /><sentence text="45 ng/mL" /><sentence text="" /><sentence text="Nefazodone is a relatively potent inhibitor of CYP3A4, a hepatic isoenzyme thought to play a major role in the metabolic elimination of zopiclone"><entity charOffset="0-10" id="DDI-PubMed.11724087.s12.e0" text="Nefazodone" /><entity charOffset="136-145" id="DDI-PubMed.11724087.s12.e1" text="zopiclone" /><pair ddi="false" e1="DDI-PubMed.11724087.s12.e0" e2="DDI-PubMed.11724087.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s12.e0" e2="DDI-PubMed.11724087.s12.e1" /></sentence><sentence text=" The substantial decrease in the plasma zopiclone concentrations observed after withdrawal of nefazodone likely reflects a drug interaction"><entity charOffset="40-49" id="DDI-PubMed.11724087.s13.e0" text="zopiclone" /><entity charOffset="94-104" id="DDI-PubMed.11724087.s13.e1" text="nefazodone" /><pair ddi="false" e1="DDI-PubMed.11724087.s13.e0" e2="DDI-PubMed.11724087.s13.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s13.e0" e2="DDI-PubMed.11724087.s13.e1" /></sentence><sentence text=" Despite the normally short elimination half-life of zopiclone, the residual sedation initially observed in this case suggests that the interaction may have clinical significance"><entity charOffset="53-62" id="DDI-PubMed.11724087.s14.e0" text="zopiclone" /></sentence><sentence text="" /><sentence text="The features observed in this case suggest the possibility of a drug-drug interaction between nefazodone and zopiclone"><entity charOffset="94-104" id="DDI-PubMed.11724087.s16.e0" text="nefazodone" /><entity charOffset="109-118" id="DDI-PubMed.11724087.s16.e1" text="zopiclone" /><pair ddi="false" e1="DDI-PubMed.11724087.s16.e0" e2="DDI-PubMed.11724087.s16.e0" /><pair ddi="false" e1="DDI-PubMed.11724087.s16.e0" e2="DDI-PubMed.11724087.s16.e1" /></sentence><sentence text=" Further prospective investigation is required to elucidate the nature and magnitude of this effect" /><sentence text="" /></document>